Group 1 - The core point of the article is that Haixi Pharmaceutical (HK02637) has announced a delay in its IPO process after completing dark pool trading, which is a rare occurrence in the Hong Kong stock market [1][2] - Haixi Pharmaceutical's dark pool trading showed strong performance with a subscription multiple exceeding 2400 times and a subscription amount over 240 billion HKD [2] - The company plans to issue approximately 11.5 million shares at a price of 86.4 HKD per share, with a notable increase of 24.54% in dark pool trading, reaching 107.6 HKD [2] Group 2 - Haixi Pharmaceutical, established in March 2012 and headquartered in Fuzhou, Fujian, operates in both generic and innovative drug development, focusing on commercialized products for various diseases [2][3] - The company has received approval for 14 generic drugs from the National Medical Products Administration, with 4 of them included in the national centralized procurement [3] - Revenue figures for Haixi Pharmaceutical during the reporting period are approximately 212 million CNY, 317 million CNY, 467 million CNY, and 249 million CNY for the years 2022, 2023, 2024, and the first five months of 2025, respectively, with net profits of approximately 69 million CNY, 117 million CNY, 136 million CNY, and 90 million CNY [3]
已暗盘交易 收涨24.54% 上市前夜海西新药突然宣布延迟上市